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Lipopolysaccharides Improve Mesenchymal Stem
Cell-Mediated Cardioprotection by MyD88
and stat3 Signaling in a Mouse Model
of Cardiac Ischemia/Reperfusion Injury
Xiaona Chu,1,* Bing Xu,1,2,* Hongyu Gao,1 Bai-Yan Li,2
Yunlong Liu,1,3 Jill L. Reiter,1,3 and Yue Wang1
Bone marrow-derived mesenchymal stem cells (MSCs) improve cardiac function after ischemia/reperfusion
injury, in part, due to the release of cytoprotective paracrine factors. Toll-like receptor 4 (TLR4) is expressed in
MSCs and regulates the expression of cytoprotective factors, cytokines, and chemokines. Lipopolysaccharide
(LPS) stimulation of TLR4 activates two distinct signaling pathways that are either MyD88 dependent or
MyD88 independent/TIR-domain-containing adapter-inducing interferon-b (TRIF) dependent. While it was
reported previously that LPS treatment improved MSC-mediated cardioprotection, the mechanism underlying
such improved effect remains unknown. To study the role of MyD88 signaling in MSC cardioprotective
activity, wild type (WT) and MyD88-/- MSCs were treated with LPS (200 ng/mL) for 24 h. WT and MyD88-/-
MSCs with or without LPS pretreatment were infused into the coronary circulation of isolated mouse hearts
(Langendorff model) and then subjected to ischemia (25min) and reperfusion (50min). Saline served as a
negative control. Both untreated and LPS-pretreated WT MSCs significantly improved postischemic recovery
of myocardial function of isolated mouse hearts, as evidenced by improved left ventricular developed pressure
and ventricular contractility assessment (ie, the rate of left ventricle pressure change over time,– dp/dt). LPS-
pretreated WT MSCs conferred better cardiac function recovery than untreated MSCs; however, such effect of
LPS was abolished when using MyD88-/- MSCs. In addition, LPS stimulated stat3 activity in WT MSCs, but
not MyD88-/- MSCs. stat3 small interfering RNA abolished the effect of LPS in improving the cardioprotection
of WT MSCs. In conclusion, this study demonstrates that LPS improves MSC-mediated cardioprotection by
MyD88-dependent activation of stat3.
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Introduction
Myocardial ischemic injury and infarction are theleading causes of death and disability worldwide. Is-
chemic injury leads to scar formation, electric uncoupling,
morphologic structure changes, and ventricular remodeling,
which have great impact on the quality of life [1]. Multiple
stem cells, such as hematopoietic stem cells (HSCs), embry-
onic stem cells, induced pluripotent stem cells, and mesen-
chymal stem cells (MSCs) have been used as therapeutic
reagents for treatingmyocardial ischemic injury and infarction
[2]. Among all the stem cell types, MSCs have multiple ad-
vantages for use in repairing the infarcted myocardium: MSCs
are safe; can be easily isolated and amplified from patients’
bone marrow; are immunologically tolerated as transplants;
and possess multilineage differentiation potential [3].
Intramyocardial injection of MSCs reduces inflammation,
fibrosis, infarct size, and ventricular remodeling, and thereby
improves cardiac function [4–7]. Although the exact mech-
anism underlying the improved benefits is not yet fully
elucidated, strong evidence indicated that MSCs displayed
beneficial cardioprotection partly through the release of
soluble paracrine factors, which reduced inflammation, de-
creased apoptosis, and inhibited cardiac remodeling [8,9].
Despite these favorable attributes, MSC-mediated pro-
tection is modest and has limited duration [10–14]. Various
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clinical trials have demonstrated that, while effective, the
delivery of MSCs to ischemic myocardium resulted in only
modest benefits. Abdel-Latif et al. [15] reported that bone
marrow cell transplantation resulted in only modest im-
provements in physiologic and anatomic parameters in pa-
tients with both acute myocardial infarction (MI) and
chronic ischemic heart disease. Moreover, although trans-
planted MSCs survived in infarcted myocardium for as
long as 6 months, no persistent benefit was observed [16].
Therefore, there is a critical need to optimize MSC-conferred
protection and identify the exact paracrine factor(s) that
mediate MSC-related therapeutic benefits.
Toll-like receptor 4 (TLR4) is highly expressed in MSCs
and regulates MSC function [17]. Upon activation by TLR4
ligands (eg, lipopolysaccharides [LPS]), TLR4 activates
two distinct signaling pathways that are either MyD88
dependent or MyD88 independent/TIR-domain-containing
adapter-inducing interferon-b (TRIF) dependent to initiate
the downstream signal transducers that then produce a variety
of paracrine factors. Although it was reported previously that
LPS preconditioning improved MSC-mediated cardioprotec-
tion in a rat model of acute MI [18], the underlying mecha-
nism remains unknown. In this study, we hypothesize that,
preconditioning MSCs with LPS improves cardioprotection
by MyD88-dependent mechanism.
Materials and Methods
Reagents
All chemicals used in this study were purchased from
Sigma Company (St. Louis, MO).
Animals
Normal adult male C57BL/6J mice and MyD88-/- mice
(25–30 g, 8–9 weeks old, B6.129P2(SJL)-Myd88tm1Defr/J) were
obtained from Jackson Labs, fed a standard diet, and acclimated
in a quiet quarantine room for 1 week before the experiments.
The animal protocol was reviewed and approved by the In-
stitutional Animal Care and Use Committee of Indiana Uni-
versity. All animals received humane care in compliance with
theGuide for theCare andUse of LaboratoryAnimals (National
Institutes of Health Publication No. 85-23, revised 1996).
Preparation of mouse bone marrow MSCs
A single-step purification method using plastic adherence
was used as previously described [19]. Briefly, MSCs were
harvested from bilateral femurs by removing the epiphyses
and flushing the shaft with complete medium (IMDM with
10% fetal bovine serum and 1% pen-strep; ThermoFisher).
Cells were disaggregated by vigorous pipetting using a sy-
ringe with a 23-gauge needle and passed through a 30 mi-
cron nylon mesh to remove remaining clumps of tissue.
Cells were washed by adding a complete medium and
centrifuged at 300 rcf for 5min at room temperature. The
cell pellets were resuspended with the complete medium and
cultured in 25 cm2 flasks (ThermoFisher) at 37C in 5%
CO2. After 48 h, nonadherent cells in suspension were dis-
carded. Fresh medium was added and replaced every 3 days
thereafter. At 90% confluence, cells were trypsinized by the
addition of 0.25% trypsin-EDTA (ThermoFisher) and re-
plated in 75 cm2 flasks. After three passages, cell surface
markers were examined using Flow Cytometry analysis.
MSCs were positive for CD44 [20] and negative for CD45,
CD11b, CD90, and CD117 [19,21]. All experiments used
cells between passages 4–10.
Small interfering RNA transfection
Small interfering RNA (siRNA) transfection was performed
as previously described [20]. Briefly, siRNA that specifically
targeted mouse stat3 was designed with the software provided
by Dharmacon siDESIGN center (Dharmacon Research, CO).
A siRNA sequence (5¢-CAGCACAACCUUCGAAGAA-3¢)
corresponding to residues 517–535 of the coding region of
mouse stat3 was selected. MSCs from the same starting cell
isolation were transfected with the aforementioned specific
stat3 siRNA at a concentration of 100nM. MSCs transfected
with scramble siRNA were used as a negative control (Ther-
moFisher). Transfection was performed with Lipofectamine
2000 (ThermoFisher) as per the manufacturers’ instructions.
Briefly, 24 h before siRNA transfection, cells were plated in
six-well plates at 5· 104 cells/well/2mL. On culture day 2,
cells were washed with Opti-MEMmedia (ThermoFisher) and
the lipofectamine-siRNA complex (100nM) was then added.
One day after transfection (day 3 in culture), the lipofectamine-
siRNA complex was washed out and the complete IMDM
mediumwith or without 200 ng/mL LPS was added to the cells
and incubated for an additional 1 day. The cell number was
counted with the aid of the TC10 Automated Cell Counter
(Bio-Rad, Hercules, CA) and cell extracts were prepared for
western blot analysis.
Isolated mouse heart perfusion (Langendorff model)
Mice were anesthetized (Pentobarbital, 60mg/kg, i.p.) and
heparinized (500U, i.p.). The heart was rapidly excised and
placed in 4C modified KH solution containing the following
(in mM): 119 NaCl, 4.7 KCl, 2.5 CaCl2, 0.5 EDTA, 25 NaH-
CO3, 1.2 KHPO4, 1.2 MgSO4, 2 Na pyruvate, 10 HEPES, and
11 dextrose. The aorta was cannulated and the heart was per-
fused under constant pressure (75mmHg) with oxygenated
(95% O2–5% CO2) KH solution at 37.5C. A left atrial resec-
tion was performed before inserting a water-filled wrap balloon
through the atrium into the ventricle. The balloon was adjusted
to mean end diastolic pressure (EDP) of 8mmHg. The hearts
were allowed to equilibrate for 15min before infusing vehicle
or MSCs and paced at 420 beats/min. During equilibration,
MSCs were trypsinized, collected, and counted. One million
viable cells were isolated and suspended in 1mL of KH solution
(37C). Over the course of 1min immediately before ischemia,
the MSC solution was infused into the coronary circulation. A
three stopcock placed above the aortic root was used to create
global ischemia. During global ischemia the hearts were placed
in a 37C degassed organ bath. Left ventricular pressure (LVP)
was continuously recorded using a PowerLab 8 preamplifier/
digitizer (AD Instruments, Inc.). The values of left ventricular
developed pressure (LVDP), +dp/dt, and -dp/dt were calculated
with the aid of PowerLab software. At the end of reperfusion,
the hearts were removed from the Langendorff device and snap-
frozen in liquid nitrogen for future analysis.
Western blotting
The cells transfected with either stat3 siRNA or scram-
ble siRNA were stimulated with 200 ng/mL LPS for 24 h.
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Western blot analysis was performed to measure stat3 ac-
tivity. Cells were lysed in cold RIPA buffer containing pro-
tease cocktail and phosphatase inhibitor cocktail 2 (Sigma).
Lysates were centrifuged at 16,000 rcf for 15min. The protein
extracts (8–10 mg/lane) were electrophoresed on a 4%–12%
Bis-Tris gel (ThermoFisher) and transferred to a nitrocel-
lulose membrane. The membranes were blocked in 5%
nonfat milk solution for 2 h and incubated with primary
antibodies for p-stat3, T-stat3, and GAPDH (Cell Signaling
Technology). After three washes with phosphate-buffered
saline (PBS) containing 1% Tween 20, membranes were
incubated in 5% nonfat milk solution containing horseradish
peroxidase-conjugated goat anti-rabbit IgG secondary anti-
body (ThermoFisher). Signal detection was performed using
SuperSignal West Pico chemiluminescent substrate (Pierce).
Films were scanned and band density was analyzed with
ImageJ software (NIH) and normalized to GAPDH.
RNA sample preparation
and RNA-sequencing assay
Wild-type (WT) or MyD88-/- MSCs were plated at
5 · 104 cells/well/mL for 24 h and then treated with LPS
(200 ng/mL) for another 24 h. Total RNA was extracted
before and after LPS treatment, following a standard pro-
tocol [25]. Experiments were conducted in triplicate.
Standard methods were used for RNA sequencing (RNA-
seq) library construction, EZBead preparation, and Next-
Gen sequencing, based on the Life Technologies SOLiD
5500xl system. Briefly, 2 mg of total RNA per sample was
used for library preparation. The ribosomal RNA (rRNA)
was first depleted using the standard protocol of RiboMinus
Eukaryote Kit for RNA-Seq (Ambion), and rRNA-depleted
RNA was concentrated using a PureLink RNA Micro Kit
(Invitrogen) with 1 volume of lysis buffer and 2.5 volumes
of 100% ethanol. After rRNA depletion, a whole transcriptome
library was prepared and barcoded per sample using the
standard protocol of SOLiD Total RNA-seq Kit (Thermo-
Fisher). Each barcoded library was quantified by quanti-
tative PCR (qPCR) using SOLiD Library TaqMan qPCR
Module (ThermoFisher) and pooled in equal molarity.
EZBead preparation, bead library amplification, and bead
enrichment were then conducted using the Life Technol-
ogies EZ Bead E80 System. Finally, sequencing by ligation
was performed using a standard single-read, 5¢-3¢ strand-
specific sequencing procedure (75 nt-read) on SOLiD 5500xl
in the Center for Medical Genomics at IU. Each SOLiD
5500xl lane can sequence *8 billion nucleotides, which is
equivalent to >100 million 75-bp reads, over 80% of which
were mappable to the reference genome.
Bioinformatics analysis for RNA-seq data
RNA-seq data analysis included the following steps: quality
assessment, sequence alignment, and alternative splicing
analysis. The RNA-seq data can be accessed through the
Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo)
with accession number GSE64568.
Data processing and quality assessment
We used SOLiD Instrument Control Software and SOLiD
Experiment Tracking System software for read quality re-
calibration. Each sequence read was scanned for low-quality
regions, and if a five-base sliding window had an average
quality score <20, the read was truncated at that position.
Any read <35 bases was discarded. Our experience suggests
that this strategy effectively eliminates low-quality reads,
while retaining high-quality regions [22–24].
Sequence alignment
We used BFAST (http://sourceforge.net/projects/bfast/)
[25] as our primary alignment algorithm due to its high
sensitivity for aligning reads on loci containing small in-
sertions and deletions, compared to the mouse reference
genome (mm9). We then used a TopHat-like strategy [26]
to align the sequencing reads containing cross-splicing
junctions using NGSUtils (http://ngsutils.org/) [22]. After
aligning the reads to a filtering index, including repeats,
rRNA, and other sequences that were not of interest, we
conducted a sequence alignment at three levels: genome,
known junctions (University of California Santa Cruz
Genome Browser), and novel junctions (based on the en-
riched regions identified in the genomic alignment). We
restricted our analysis to uniquely aligned sequences with
no more than two mismatches.
Differential expression analysis
The edgeR package [27] was used to identify genes dif-
ferentially expressed between control and LPS groups. False
discovery rate (FDR) was calculated within edgeR using
Benjamini and Hochberg correction [28]. Analysis was lim-
ited to those genes with ‡1 count per million in at least two of
the samples in one of the conditions.
Heat map analysis
Heat map of the differentially expressed genes induced by
LPS in WT MSC was generated with the R package Com-
plexHeatmap [29].
Pathway and regulatory analysis
Qiagen ingenuity pathway analysis was used to identify
pathways that are significantly enriched in differentially ex-
pressed (FDR £0.05) genes. Upstream regulator analysis uses
the curated knowledge base to identify molecules that could
possibly be responsible for the observed changes in gene
expression, based on a z score indicating whether the activ-
ity of a specific regulatory factor is stimulated or inhibited. A
detailed definition of z-score can be found in the Qiagen
white paper (http://pages.ingenuity.com/rs/ingenuity/images/
0812%20upstream_regulator_analysis_whitepaper.pdf).
stat3 binding site prediction
Putative stat3 binding sites were predicted based on
the promoter sequences (-1,500 bp to +500 bp from the
transcription start sites) of the genes to be evaluated.
Position-specific score matrices were used to calculate the
possibility of a specific transcription factor (stat3) binding
at one genomic locus, as described previously [30]. The
highest matching score during this scanning was used to
evaluate the binding potential of the stat3 in the promoter
region.
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Statistical analysis on phenotype data
All reported values were mean – standard error of the
mean, and P < 0.05 was considered statistically significant.
LVDP, +dp/dt, and -dp/dt were as percentage of baseline
during equilibrium. Data were compared using one-way or
two-way analysis of variance with post hoc Bonferroni.
Results
LPS improved MSC-mediated cardioprotection
in WT, but not MyD88-/- MSCs in an isolated
mouse Langendorff heart preparation
To examine whether LPS improved MSC-conferred pro-
tection, plastic-adherent cells from mouse bone marrow from
WT and MyD88-/- mice were isolated and propagated under
normal cell culture conditions (5% CO2 at 37C, 90% hu-
midity) [8]. These cells were negative for the HSC marker
CD45, as well as CD11b, CD106, CD117, and CD90, and
were positive for stem cell antigen-1 and the MSC marker
CD44 [8]. We have also demonstrated previously that puri-
fied stromal cells were able to differentiate into adipocytes
and osteoblasts, suggesting that these cells indeed had MSC
characteristics [8]. As shown in Fig. 1, isolated Langendorff
mouse hearts infused with LPS-pretreated MSCs demon-
strated improved functional recovery compared to un-
treated MSC and vehicle groups. In comparison with the
baseline, postischemic LVDP, +dp/dt, and -dp/dt were
markedly decreased, but EDP was greatly elevated in all
treatment groups (Fig. 1). Intracoronary infusion of WT
MSCs and WT MSCs + LPS significantly enhanced postis-
chemic recovery of myocardial function as exhibited by
LVDP, +dp/dt, and -dp/dt compared to vehicle (P < 0.05).
The WT MSCs + LPS group displayed an even better re-
covery than untreated WT MSCs from ischemic injury
(Fig. 1). In contrast, LPS did not improve the cardioprotective
effect of MyD88-/- MSCs. Although MyD88-/- MSCs ex-
hibited a similar cardioprotection effect as untreated WT
MSCs, LPS failed to further potentiate their cardioprotective
effect. Notably, the value of EDP, an index of heart injury,
progressively increased to a relatively higher level after is-
chemia in all groups, indicating significant cardiac injury
(Figs. 1G and 2F). All hearts receiving cell infusion demon-
strated smaller EDP compared to vehicle (Figs. 1G and 2F).
Taken together, LPS significantly improved MSC-mediated
cardioprotection in WT, but not in MyD88-/- MSCs.
A
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B C
FIG. 1. LPS improved the cardioprotection derived from WT MSCs. WT or MyD88-/- MSCs, with or without LPS
pretreatment, were infused into the coronary circulation before global ischemia. (A–C) Representative LVP recording from
mouse hearts infused with vehicle, WT MSCs, and MSCs + LPS. (D–G) Plots represent changes in LVDP (% of equi-
librium, D), +dP/dt (% of equilibrium, E), -dP/dt (% of equilibrium, F), and EDP (G) over time. Mouse hearts were infused
with vehicle (square, n = 5 mouse hearts), WT MSCs (circle, n = 6), or MSCs + LPS (triangle, n = 5). Results are reported as
the mean – SEM. *P < 0.05 versus vehicle; #P< 0.05 versus WT MSC group, as determined by two-way ANOVA followed
by Tukey post hoc test. Arrows represent the starting time points of ischemia. ANOVA, analysis of variance; EDP, end-
diastolic pressure; Eq, equilibrium; Is, ischemia; LPS, lipopolysaccharides; LVDP, left ventricular developed pressure;
LVP, left ventricular pressure; MSC, mesenchymal stem cell; Re, reperfusion; SEM, standard error of the mean; TNF,
tumor necrosis factor; WT, wild type.
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MyD88-/- MSCs exhibited a slower rate
of proliferation and did not activate stat3
in response to LPS
We reported previously that increased stat3 activity
improved MSC-mediated cardioprotection in a paracrine
manner [8]. To further examine the crosstalk between MyD88-
dependent signaling and stat3 activity, WT and MyD88-/-
MSCs were stimulated with LPS. As shown in Fig. 3A, B, LPS
significantly activated stat3 in WT MSCs, but not in MyD88-/-
MSCs. In addition, MyD88-/- MSCs proliferated at a much
slower rate, compared to WT cells (Fig. 3C). LPS at 200ng/mL
did not change the rate of proliferation in either WT or
MyD88-/- cells (data not shown).
LPS stimulation changed the global gene
expression in MSC
To investigate LPS-induced transcriptome changes in
mouse MSC, RNA-seq was conducted before and after LPS
treatment [8]. WT or MyD88-/- MSCs were plated at 5 · 104
cells/well in six-well plates for 24 h and further treated with
LPS (200 ng/mL) for another 24 h. Experiments were con-
ducted in triplicates. LPS was found to regulate global gene
expression of WT MSCs.
As shown in Supplementary Table S1, the expression
levels of 295 genes were significantly altered after LPS
treatment (FDR <0.05). The expression levels of the 295
genes in all the four experimental conditions were demon-
strated in Fig. 4. Further pathway analysis suggested that
62 of the 295 genes were related to inflammatory response.
Specifically, the P values for 47 subcategories of inflam-
matory response were significantly enriched (Supplementary
Table S2) with P values between 1.4 · 10-3 and 4.4 · 10-9.
This is consistent with the current knowledge that MSCs
regulate immune and inflammatory responses, and facilitate
the repair of damaged tissues, including cardiac tissues.
We observed increases in the stat3 activity. Five genes
known to be activated by stat3 all showed increased ex-
pression levels. These included chemokine (C-C motif) li-
gand 2 (CCL2), hypoxia inducible factor 1 alpha subunit
(HIF1A), schlafen 2 (which is known to be altered by LPS),
guanylate binding protein 2, and nuclear factor of j light
polypeptide gene enhancer in B cell inhibitor, f (NFKBIZ).
In addition, among the four genes that are known to be
inhibited by stat3, three showed decreased expression lev-
els, including insulin-like growth factor binding protein 5,
transcription factor 4, and hyaluronan synthase 2. Given the
known functions of these stat3 target genes in proin-
flammation and tissue growth, we hypothesize that LPS
alters the global gene expression profiles of MSCs, in part,
through stat3 pathways.
Interestingly, most LPS-induced changes were abolished
in MyD88-/- MSCs. Among the 295 genes whose expres-
sion levels were altered in WT MSCs, only eight were
significantly different in MyD88-/- animals. These eight
genes were noncoding genes, seven of which were small
nucleolar RNAs and one was a small Cajal body-specific
A B
C D E F
FIG. 2. LPS failed to improve the cardioprotection of MyD88-/- MSCs. MyD88-/- MSC, with or without LPS pre-
treatment, were infused into the coronary circulation. (A, B) Representative LVP recording traces from hearts infused with
MyD88-/- MSCs and MyD88-/- MSCs + LPS as a function of time (n= 5). The LVDP in MyD88-/- group (square) and
MyD88-/- MSCs + LPS group (circle, n= 5) is presented. The line graphs represent changes in LVDP (% of equilibrium,
C), +dP/dt (% of equilibrium, D), -dP/dt (% of equilibrium, E), and EDP (F) over time. Results are reported as the
mean – SEM. Arrows represent the starting time points of ischemia.
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RNA. This result suggests that LPS-induced changes in WT
MSCs were largely abolished in the MyD88-/- MSCs.
stat3 ablation abolished the effect of LPS
in improving MSC-mediated cardioprotection
following ischemia/reperfusion (I/R) injury
To examine the role of stat3 in MSC-conferred cardio-
protective effect, hearts were randomized into three groups:
saline, MSCs + LPS + scramble siRNA, and MSCs + LPS +
stat3 siRNA. After establishing the mouse I/R model, MSCs
(1 · 105 cells in 1mL of PBS) were infused into the coro-
nary circulation before global ischemia. The representative
recording traces of LVP are shown in Fig. 5A–C. As shown
in Fig. 5, LPS pretreatment improved the cardioprotection
of scramble siRNA-transfected cells, but not stat3-ablated
cells. Heart infused with LPS-pretreated, scramble siRNA-
transfected cells shows better postischemic functional re-
covery, compared to vehicle and stat3-ablated cells, as
evidenced by improved LVDP, +dp/dt, and -dp/dt. The
postischemic functional recovery of the stat3 siRNA group
was down to a level of the vehicle group (Fig. 5). Among the
three groups, no differences were observed in EDP, sug-
gesting similar I/R injury (Fig. 5G).
Discussion
We herein report that LPS pretreatment improved MSC-
mediated cardioprotection in mouse models of cardiac I/R
injury. However, such LPS effects were abolished when
using MSCs isolated from MyD88-/- mice. We also dem-
onstrated that MyD88-/- MSCs proliferated much more
slowly and failed to activate stat3 in response to LPS
stimulation compared to WT MSCs. The ablation of stat3
abolished the protective effect of WT MSCs in isolated
mouse heart I/R model. Most LPS-induced global gene
expression changes were abolished in MyD88-/- MSCs.
Collectively, this experimental evidence strongly supports
the conclusion that LPS improves MSC-mediated cardio-
protection by MyD88-dependent activation of stat3.
Ischemic heart disease occurs in*40% of the population
older than 40 years and is the leading cause of death
worldwide. During ischemia, the heart is deprived of oxygen
and nutrients, leading to apoptosis and necrosis of cardio-
myocytes and endothelial cells [31,32]. Subsequent resto-
ration of blood flow results in additional damage to the
myocardium, which is known as I/R injury [32–34]. A more
effective therapy is urgently needed and MSCs are emerging
as a promising therapeutic agent for heart repair. In recent
years, many clinical trials have been performed, accompa-
nied by the improvement of LVDP, EF, and FS. However,
such beneficial effects were modest and only lasted 6
months [35,36]; at 5 years follow-up, the helpful effects
were no longer significant [37].
Researchers have proposed many hypotheses to explain
mechanisms of MSC-enhanced cardiac function, including
trans-differentiation, electrophysiological coupling, and para-
crine protection [9]. However, clinical trials showed that re-
tention of transplanted cells was low in the heart, most of
which were lost through the vasculature and accumulated
FIG. 3. MyD88-/- MSCs did not activate stat3 in response to LPS stimulation and exhibited a slower rate of proliferation.
WT and MyD88-/- MSCs were stimulated with or without LPS (200 ng/mL) for 24 h. Phosphorylated stat3 levels in protein
extracts from all groups were analyzed by western blot. (A) Representative blot is shown. Three technical replicates per
group are presented. (B) Western signals from images of scanned X-ray films were analyzed, normalized to GAPDH, and
quantified as pixel densities. (C) Fifteen thousand cells from both genotypes were plated per well in six-well plates. Cell
numbers were counted at 5 days or 8 days. *P < 0.05 versus control MSCs as determined by one-way ANOVA followed by
Tukey post hoc test.
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in lung, spleen, and pancreas; as a consequence, few cells
were found engrafted in the heart [38]. In addition, survival
of transplanted MSCs in the inflammatory environment of
infarcted myocardium was low, as typically 90% of cells
died within 1 week [39]. Thus, the number of transplanted
cells was insufficient to explain significant cardiac function
improvement after ischemic injury. A mechanism of para-
crine factors was reported by many researchers to explain
MSC-mediated heart function enhancement in the short term
[9]. MSCs can secrete a broad variety of cytokines, che-
mokines, and growth factors, which promote neovascu-
larization, cardiac metabolism, and cardiac regeneration.
These paracrine factors could exert cardioprotection through
the following mechanisms: (1) increasing blood flow within
ischemic myocardium to alleviate cardiomyocyte necrosis
and apoptosis; (2) reducing the distance between the is-
chemic tissue area and the nearest blood vessels through
angiogenesis; (3) enhancing the permeability of blood
vessel to plasma and micromolecules [40]; and (4) re-
cruiting MSCs and HSCs of the circulating blood stem
cells to the injured myocardium.
TLR4 is a type I transmembrane glycoprotein that is
expressed in MSCs [41]. Upon stimulation by its ligand
LPS, TLR4 activates two distinct signaling pathways that
are MyD88 dependent or TRIF dependent, ultimately lead-
ing to the activation of transcription factors. LPS has an
antiapoptotic effect in neonatal mouse myocytes exposed to
hypoxia, but this effect of LPS was neutralized in MyD88
FIG. 4. Heat map of the
LPS induced differentially
expressed genes in WT and
MyD88-/- MSCs. The rows
are genes and the columns are
samples. The paracrine fac-
tors and intracellular signaling
molecules were labeled.
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KO myocytes [42]. In this study, we demonstrated that
LPS enhanced WT-MSC-mediated postischemic recovery
after I/R injury, but not MyD88-/- MSC-mediated recovery.
In addition, LPS stimulated a gene expression profile in WT
cells, whereas most LPS-induced changes were abolished in
MyD88-/- MSCs. Such findings indicate that TLR4 acti-
vates transcription factors through a MyD88-dependent
signaling pathway, which is consistent with the results of
Zhu et al. [42].
stat3 is a transcription factor that conducts a funda-
mental role in physiological homeostasis. Deregulated
stat3 signaling is sufficient to induce dilated cardiomy-
opathy and adverse remodeling after MI [43,44]. stat3 is a
multifaceted molecule in the heart and is responsible for
communication between cardiomyocytes and cardiac fi-
broblasts, modulation of the microenvironment, and reg-
ulation of cardiac inflammation, namely participating in
cardiomyocyte growth, survival, sarcomere architecture,
energetics, and metabolism [43–45]. In this study, we
found that LPS can markedly improve MSC-mediated
cardioprotection in isolated hearts of a mouse I/R model
and that stat3 ablation in MSCs abolished these beneficial
effects (Fig. 4). Because the experimental period was too
short for neoangiogenesis to occur, such findings may
suggest that stat3 modulates MSC-mediated protection by
regulating the release of paracrine factors.
We reported previously that stat3 ablation in MSCs resulted
in a decreased expression of the angiogenic factor vascular
endothelial growth factor (VEGF), upregulation of the proin-
flammatory chemokine RANTES, and attenuated MSC-
mediated cardioprotection [8]. It is possible that stat3 could
exert its beneficial effect, at least in part, through the expression
of paracrine factors and intracellular signaling molecules. In
Table 1, the gene expression level of paracrine factors, in-
cluding CCL2/monocyte chemotactic protein (MCP)1, CCL7,
fibroblast growth factor (FGF)7, CCL9, Hif1a, NFKBIZ, ler3,
Fas, and Pak3, was found to be enhanced by LPS induction in
WT MSCs, while the expression of Cxcl12/SDF-1, lgf1, and
lgfbp5 was reduced. Among the upregulated paracrine factors,
CCL2/MCP1 had the highest, 4.99 log2-fold-change, followed
by CCL7, which was enhanced 4.04 log2-fold. However, in the
Myd88-/- MSCs, the effect of LPS on the global gene ex-
pressionwas abolished. CCL2 and CCL7 are both chemokines,
which are a subgroup of cytokines with the specific function
of chemoattraction (chemotactic cytokines) [46]. It is already
known that chemokines interfere with key events followingMI:
they modulate the inflammatory response, the molecular and
cellular composition of the scar, and the implicit remodeling of
A
D E F G
B C
FIG. 5. Ablation of stat3 abolished the effect of LPS in improving MSC-mediated protection. MSCs with or without stat3
siRNA transfection were infused into the coronary circulation. (A–C) Representative LVP recording traces from hearts
infused with vehicle, scramble control siRNA-treated MSCs + LPS, and stat3 siRNA-treated MSCs + LPS as a function of
time (n= 5). The LVDP in vehicle (square), stat3 siRNA group (circle), and scramble siRNA group (triangle, n = 5) is
presented. The line graphs represent changes in LVDP (% of equilibrium, D), +dP/dt (% of equilibrium, E), -dP/dt (% of
equilibrium, F), and EDP (G) over time. Results are reported as the mean –SEM. *P < 0.05 versus vehicle; #P < 0.05 versus
stat3 siRNA + LPS group, as determined by two-way ANOVA followed by Tukey post hoc test. Arrows represent the
starting time points of ischemia. siRNA, small interfering RNA.
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the ventricle and heart function [2]. CCL2 is referred to MCP1
or small inducible cytokine A2, which can recruit monocytes,
memory T cells, and dendritic cells to the sites of inflammation
produced by either tissue injury or infection. It was reported that
in animal models, CCL2 is upregulated after MI, and is im-
portant in angiogenesis and collateralization both in vivo and in
vitro [2]. CCL7, also known as MCP3, has been found to be
crucially involved both in MSCs homing to the ischemic
myocardium as well as in their intramyocardial migration and
survival. Moreover, it was reported in a rat model that, over-
expression of CCL7 induced homing of repeatedly adminis-
trated MSCs 1 month after MI, which in turn improved heart
remodeling and preserved heart function [47].
The expression of FGF7 and NFKBIZ is enhanced 2.23
and 2 log2-fold by LPS, respectively. The FGF family is a
highly complex family of growth factors. In the adult, FGFs
are important in wound healing, tissue repair, metabolism,
and homeostasis [48]. FGF7, also known as keratinocyte
growth factor, is expressed specifically in mesenchyme.
Treatment of injured epithelia with FGF7 results in an im-
proved wound-healing response. The mitogenic and cyto-
protective properties of FGF7 are already being put to
advantageous use in the clinic [49].
Nuclear factor kappa beta inhibitor zeta is a protein
encoded by Nfkbiz gene, and it functions as a transcrip-
tional regulator of genes encoding intermediates of in-
flammation. The significantly increased expression of
Nfkbiz was observed in cells subjected to I/R both in vivo
and in vitro [50].
In summary, all these observations support the notion that
the MyD88-dependent pathway(s) promote MSC-mediated
cardioprotection through a MyD88/stat3-dependent, tran-
scriptional induction of protective paracrine factors.
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